File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Different trajectories of neurological soft signs progression between treatment-responsive and treatment-resistant schizophrenia patients

TitleDifferent trajectories of neurological soft signs progression between treatment-responsive and treatment-resistant schizophrenia patients
Authors
KeywordsNeurological soft signs
Treatment resistance
First-episode schizophrenia
Longitudinal
Clozapine
Issue Date2021
PublisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/jpsychires
Citation
Journal of Psychiatric Research, 2021, v. 138, p. 607-614 How to Cite?
AbstractSchizophrenia patients exhibit subtle and non-localizing neurological abnormalities, known as neurological soft signs (NSS). Life-span evidence suggests that NSS vary along the course of schizophrenia. An association between NSS and treatment response has been proposed, suggesting that NSS reflect the underlying neuropathology development in schizophrenia. However, few studies have investigated the relationship between NSS and treatment resistance in first-episode schizophrenia patients. We conducted a longitudinal study on 52 first-episode schizophrenia patients, who were assessed at baseline, the sixth month, and the fifth year using the abridged version of the Cambridge Neurological Inventory. The trajectories of NSS between 29 treatment-responsive patients (with full symptomatic remission) and 23 treatment-resistant patients (who received clozapine) were compared using mixed model ANOVA. We also controlled for the effect of age and estimated IQ, using a mixed ANCOVA model. Although the two schizophrenia groups had comparable NSS at the baseline, their trajectories of NSS differed significantly. Compared with their treatment-responsive counterparts, treatment-resistant schizophrenia patients had worsening of NSS over time. Our findings support the potential utility of NSS in identifying treatment resistance in first-episode schizophrenia. Progressive worsening of NSS in treatment-resistant schizophrenia patients may reflect the development of underlying neuropathology. Further studies using large samples of treatment-resistant schizophrenia patients are needed.
Persistent Identifierhttp://hdl.handle.net/10722/299784
ISSN
2023 Impact Factor: 3.7
2023 SCImago Journal Rankings: 1.553
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLui, SSY-
dc.contributor.authorYip, SSL-
dc.contributor.authorWang, Y-
dc.contributor.authorHung, KSY-
dc.contributor.authorHo, KKY-
dc.contributor.authorTsang, KCM-
dc.contributor.authorYeung, HKH-
dc.contributor.authorCheung, EFC-
dc.contributor.authorChan, RCK-
dc.date.accessioned2021-05-26T03:29:00Z-
dc.date.available2021-05-26T03:29:00Z-
dc.date.issued2021-
dc.identifier.citationJournal of Psychiatric Research, 2021, v. 138, p. 607-614-
dc.identifier.issn0022-3956-
dc.identifier.urihttp://hdl.handle.net/10722/299784-
dc.description.abstractSchizophrenia patients exhibit subtle and non-localizing neurological abnormalities, known as neurological soft signs (NSS). Life-span evidence suggests that NSS vary along the course of schizophrenia. An association between NSS and treatment response has been proposed, suggesting that NSS reflect the underlying neuropathology development in schizophrenia. However, few studies have investigated the relationship between NSS and treatment resistance in first-episode schizophrenia patients. We conducted a longitudinal study on 52 first-episode schizophrenia patients, who were assessed at baseline, the sixth month, and the fifth year using the abridged version of the Cambridge Neurological Inventory. The trajectories of NSS between 29 treatment-responsive patients (with full symptomatic remission) and 23 treatment-resistant patients (who received clozapine) were compared using mixed model ANOVA. We also controlled for the effect of age and estimated IQ, using a mixed ANCOVA model. Although the two schizophrenia groups had comparable NSS at the baseline, their trajectories of NSS differed significantly. Compared with their treatment-responsive counterparts, treatment-resistant schizophrenia patients had worsening of NSS over time. Our findings support the potential utility of NSS in identifying treatment resistance in first-episode schizophrenia. Progressive worsening of NSS in treatment-resistant schizophrenia patients may reflect the development of underlying neuropathology. Further studies using large samples of treatment-resistant schizophrenia patients are needed.-
dc.languageeng-
dc.publisherPergamon. The Journal's web site is located at http://www.elsevier.com/locate/jpsychires-
dc.relation.ispartofJournal of Psychiatric Research-
dc.subjectNeurological soft signs-
dc.subjectTreatment resistance-
dc.subjectFirst-episode schizophrenia-
dc.subjectLongitudinal-
dc.subjectClozapine-
dc.titleDifferent trajectories of neurological soft signs progression between treatment-responsive and treatment-resistant schizophrenia patients-
dc.typeArticle-
dc.identifier.emailLui, SSY: lsy570@hku.hk-
dc.identifier.emailYip, SSL: yss151@HKUCC-COM.hku.hk-
dc.identifier.emailHung, KSY: ksyhung@HKUCC-COM.hku.hk-
dc.identifier.emailHo, KKY: karenho2@hku.hk-
dc.identifier.emailChan, RCK: rckchan@hkucc.hku.hk-
dc.identifier.authorityLui, SSY=rp02747-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jpsychires.2021.05.018-
dc.identifier.pmid34004397-
dc.identifier.scopuseid_2-s2.0-85105802902-
dc.identifier.hkuros322503-
dc.identifier.volume138-
dc.identifier.spage607-
dc.identifier.epage614-
dc.identifier.isiWOS:000658540400017-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats